Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Fibrosis: Mechanisms of Disease & Emerging Therapeutic Approaches

Reporter: Aviva Lev-Ari, PhD, RN

| MerckBostonSymposium.com

ABOUT THIS 1 DAY SYMPOSIUM:

The Boston Fibrosis Symposium will enable networking and sharing of the latest research and insights among local academic researchers, drug discovery scientists and medical experts. The meeting will provide an opportunity for participants not only to learn about the pathogenesis of fibrotic disease, but will also promote fibrosis research and facilitate new collaborations toward discovery, development and use of new anti-fibrotic therapies.

Fibrosis is a pathologic component of a variety of diseases that impacts multiple organs. Advances in the basic science of the underlying pathology have been accompanied by an increase in the number of mechanisms being tested in the clinic and activity in the pharmaceutical and biotech industry. Merck Research Laboratories’ Fibrosis: Mechanisms of Disease & Emerging Therapeutic Approaches Symposium will offer a forum for networking and sharing of the latest research and insights among local academic researchers, drug discovery scientists and medical experts. This one day Boston Symposium will provide an opportunity for participants to not only learn about the pathogenesis of fibrotic disease, but will also promote fibrosis research and facilitate new collaborations toward discovery, development and use of new anti-fibrotic therapies. Join key opinion leaders from the local Boston academic and biotech community as we bring together researchers from diverse fields of study to explore the commonalities and emergent opportunities for intervention.

Who Should Attend:

Academic, Industry and Healthcare Professionals interested in the discovery and development of new therapies for fibrotic diseases.

Keynote Speaker:

Benjamin D. Humphreys M.D.,
Ph.D, Chief, Division of Renal Diseases; Chromalloy Associate Professor of Medicine, Washington University School of Medicine in St. Louis

Co-Chairs:

Andrew Tager, M.D.,
Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital (MGH)

Mark Erion, Ph.D.,
Vice President and Discovery Therapeutic Area Head, CV and Diabetes,
Merck Research Laboratories

Co-Produced By:

Cambridge Healthtech Institute

250 First Avenue, Suite 300 | Needham, MA 02494 | P: 781.972.5400 | E: chi@healthtech.com

www.healthtech.com

SOURCE

From: Merck Boston Event <bethanyg@healthtech.com>

Date: Tuesday, October 13, 2015 at 11:15 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Free 1 Day Symposium – Fibrosis: Mechanisms of Disease & Emerging Therapeutic Approaches – Register Now